vs
Side-by-side financial comparison of Aterian, Inc. (ATER) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $15.1M, roughly 1.1× Aterian, Inc.). Journey Medical Corp runs the higher net margin — -7.8% vs -52.5%, a 44.8% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -38.5%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -13.5%).
Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
ATER vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.1M | $16.1M |
| Net Profit | $-7.9M | $-1.2M |
| Gross Margin | 56.1% | — |
| Operating Margin | -51.1% | -2.8% |
| Net Margin | -52.5% | -7.8% |
| Revenue YoY | -38.5% | 27.3% |
| Net Profit YoY | -512.2% | -182.0% |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.1M | $16.1M | ||
| Q3 25 | $19.0M | $17.0M | ||
| Q2 25 | $19.5M | $15.0M | ||
| Q1 25 | $15.4M | $13.1M | ||
| Q4 24 | $24.6M | $12.6M | ||
| Q3 24 | $26.2M | $14.6M | ||
| Q2 24 | $28.0M | $14.9M | ||
| Q1 24 | $20.2M | $13.0M |
| Q4 25 | $-7.9M | $-1.2M | ||
| Q3 25 | $-2.3M | $-2.3M | ||
| Q2 25 | $-4.9M | $-3.8M | ||
| Q1 25 | $-3.9M | $-4.1M | ||
| Q4 24 | $-1.3M | $1.5M | ||
| Q3 24 | $-1.8M | $-2.4M | ||
| Q2 24 | $-3.6M | $-3.4M | ||
| Q1 24 | $-5.2M | $-10.4M |
| Q4 25 | 56.1% | — | ||
| Q3 25 | 56.1% | — | ||
| Q2 25 | 54.3% | — | ||
| Q1 25 | 61.4% | — | ||
| Q4 24 | 63.4% | 82.3% | ||
| Q3 24 | 60.3% | 63.9% | ||
| Q2 24 | 60.4% | 56.0% | ||
| Q1 24 | 65.1% | 47.7% |
| Q4 25 | -51.1% | -2.8% | ||
| Q3 25 | -10.7% | -9.0% | ||
| Q2 25 | -23.1% | -19.2% | ||
| Q1 25 | -24.1% | -25.3% | ||
| Q4 24 | -6.5% | 17.7% | ||
| Q3 24 | -6.6% | -19.8% | ||
| Q2 24 | -11.5% | -19.7% | ||
| Q1 24 | -26.1% | -77.4% |
| Q4 25 | -52.5% | -7.8% | ||
| Q3 25 | -12.0% | -13.6% | ||
| Q2 25 | -25.0% | -25.3% | ||
| Q1 25 | -25.4% | -31.0% | ||
| Q4 24 | -5.3% | 12.1% | ||
| Q3 24 | -6.8% | -16.3% | ||
| Q2 24 | -13.0% | -22.6% | ||
| Q1 24 | -25.5% | -80.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.17 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $15.2M | $31.9M |
| Total Assets | $29.6M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | $24.1M | ||
| Q3 25 | $7.6M | $24.9M | ||
| Q2 25 | $10.5M | $20.3M | ||
| Q1 25 | $14.3M | $21.1M | ||
| Q4 24 | $18.0M | $20.3M | ||
| Q3 24 | $16.1M | $22.5M | ||
| Q2 24 | $20.3M | $23.9M | ||
| Q1 24 | $17.5M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $15.2M | $31.9M | ||
| Q3 25 | $22.6M | $25.9M | ||
| Q2 25 | $24.3M | $19.2M | ||
| Q1 25 | $27.0M | $21.5M | ||
| Q4 24 | $30.0M | $20.1M | ||
| Q3 24 | $30.6M | $10.9M | ||
| Q2 24 | $30.9M | $11.3M | ||
| Q1 24 | $33.0M | $13.0M |
| Q4 25 | $29.6M | $94.6M | ||
| Q3 25 | $40.1M | $85.2M | ||
| Q2 25 | $45.4M | $81.2M | ||
| Q1 25 | $49.8M | $85.0M | ||
| Q4 24 | $49.5M | $80.2M | ||
| Q3 24 | $52.1M | $64.0M | ||
| Q2 24 | $59.9M | $65.2M | ||
| Q1 24 | $55.7M | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.0M | $-6.3M |
| Free Cash FlowOCF − Capex | $-1.0M | — |
| FCF MarginFCF / Revenue | -6.9% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.0M | $-6.3M | ||
| Q3 25 | $-1.6M | $-2.4M | ||
| Q2 25 | $-4.4M | $-942.0K | ||
| Q1 25 | $-3.9M | $-2.8M | ||
| Q4 24 | $-9.0K | $2.2M | ||
| Q3 24 | $-722.0K | $-1.2M | ||
| Q2 24 | $2.9M | $-5.2M | ||
| Q1 24 | $-6.0K | $-5.0M |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-1.6M | — | ||
| Q2 25 | $-4.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $-42.0K | — |
| Q4 25 | -6.9% | — | ||
| Q3 25 | -8.4% | — | ||
| Q2 25 | -22.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | -0.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATER
| Sales Channel Directly To Consumer | $13.1M | 87% |
| Heating Cooling And Air Quality | $2.1M | 14% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
